TYRA-300

March 2, 2026 — Tyra Biosciences (Nasdaq: TYRA) reported Q4 and full-year 2025 financial results and outlined its “dabogratinib 3x3” strategy to advance oral dabogratinib (FGFR3-selective inhibitor) in three late-stage–oriented Phase 2 programs targeting low-grade upper tract urothelial carcinoma (LG-UTUC), FGFR3-altered low-grade intermediate-risk non–muscle invasive bladder cancer (IR NMIBC), and achondroplasia (ACH).

Key clinical updates: SURF303 (Phase 2a/b LG-UTUC; ~85% tumors FGFR3-driven) is starting up with first patient dosing expected in 2026. SURF302 (Phase 2 IR NMIBC) expanded sites in Q4 2025; initial 3‑month complete response data are expected by end of 1H 2026. BEACH301 (Phase 2 ACH in children 3–10) cleared 2 of 4 dose levels in a safety sentinel cohort with no safety events reported; interim sentinel results including 6‑month average height velocity and safety are expected in 2H 2026. The SURF301 metastatic urothelial cancer study is no longer recruiting; data were presented at ASCO GU 2026 to support dose selection.

Financially, TYRA ended 2025 with $256.0M in cash/cash equivalents/marketable securities (runway through at least 2027). FY2025 net loss was $119.9M (vs. $86.5M in 2024), with R&D $102.9M and G&A $29.8M. TYRA also appointed a COO and Chief Regulatory Officer and noted portfolio prioritization, including exiting metastatic bladder cancer.